ONCT News and Press, Oncternal Therapeutics Inc. From 04/18/24

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-5...

2024-04-06 21:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatme...

2024-03-08 16:52:09 ET More on Oncternal Therapeutics Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript Oncternal slips after early data for lymphoma therapy Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings ...

2024-03-07 20:46:07 ET Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Results Conference Call March 07, 2024 05:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call...

2024-03-07 16:02:52 ET More on Oncternal Therapeutics Oncternal slips after early data for lymphoma therapy Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information for Oncternal T...

Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the second quarter...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-06 17:20:25 ET More on Oncternal Therapeutics Oncternal slips after early data for lymphoma therapy Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information for Oncternal T...

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. finan...